Henry Han (@HanCardiomd) header
Henry Han (@HanCardiomd) profile picture

Henry Han

@HanCardiomd

Cardiologist MBBS, MD, FACC, FESC | Physician-Sci & Researcher MPH, DMSc | #HeartFailure 🧑‍⚕️| #HFA Committee @escardio | Content Catalyst @TCTMD

 USA | Earth 🌎
linktr.ee/hannaung
Joined July 2017
  • Tweets18.9K
  • Following846
  • Followers16.8K
5.6KMedia
Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)Photo by Henry Han (@HanCardiomd)
What’s new in heart failure? September 2026 academic.oup.com/eurjhf/adva… @ESC_Journals #EJHF @EJHFEiC @GianluSava
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
7
76
1
215
10,226
Now in @JACCJournals by #HFC member @JavedButler1 et al. A new study estimates the potential impact of recently approved cardiometabolic therapies and risk-based prevention strategies on the future burden of HF in the U.S. jacc.org/doi/10.1016/j.jchf.…
Image from HF Collaboratory (@hfcollaboratory)
1
2
5
179
Honored to receive the Sir William Osler Young Investigator Award from the Interurban Clinical Club, founded by Osler in 1905. 🏅 A legacy of discovery & mentorship I’m grateful to share with our mentors, collaborators & trainees. ❤️ @Yale
Image from Jennifer Kwan MD PhD (@jennkwanMDPhD)
1
5
25
1,511
Henry Han retweeted
Circulation (@CircAHA) profile picture
Circulation@CircAHANov 9
Can one risk equation predict two HF phenotypes? PREVENT-HF predicted both #HFpEF and #HFrEF across community cohorts and health system samples, with modestly better discrimination for HFpEF. #ScientificSessions26 @AHAScience ahajrnls.org/4zBqgoW
Image from Circulation (@CircAHA)
5
9
17
2,667
LBBP Vs RVP for AV Block (#OptimPacing Trial) 📍 702 patients with AV block randomized 1:1 to #LBBP vs #RVP); 685 included in modified intention-to-treat analysis 📍Trial was stopped early for benefit at prespecified interim analysis. 📍At median 35.1 months, primary composite of death, HF 🏥, or pacing-induced cardiomyopathy occurred in 16 (LBBP) vs 35 (RVP). 🎯 4-year event rate: 8.5% vs 19.2%; HR 0.41 (95% CI 0.23–0.75), P=0.003. Serious non-procedural adverse events were similar (11.8% vs 9.3%). nejm.org/doi/full/10.1056/NE… @NEJM #LBBP #CardiacPacing #HeartFailure #AHA26 #ScientificSessions26
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
1
14
44
3,489
Interesting findings from OPTIMAL-DIABETES trial demonstrating intensive BP-lowering (SBP <120 vs. <140) in Brazilian T2DM cohort + high CV risk did not significantly reduce the occurrence of major cardiovascular events! @AHAScience #ScientificSessions26
Henry Han (@HanCardiomd) profile pictureHenry Han
@HanCardiomdNov 7
Intensive BP Lowering in Patients with Type 2 DM : #OPTIMAL-DIABETES Trial 👥📍 9,476 patients | Mean age 64.7 years | 62% women 📍 Achieved SBP: 121.8 vs 135.4 mm Hg (intensive vs standard), Median follow-up: 4.0 years 📍 Primary outcome: 6.0% vs 6.7% — HR 0.90 (95% CI 0.77–1.06), P=0.20 → no significant benefit ⚠️📍 Serious AEs: 14.9% vs 14.6% — similar between groups nejm.org/doi/full/10.1056/NE… #ScientificSessions26 #AHA26 @AHAScience @NEJM
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
3
9
753
Reporting the newest #hypertension discovery from @AHAScience #ScientificSessions26! In the era of novel BP-lowering modalities, hyperaldosteronism remission after extended aldosterone synthase inhibition with substantial BP and ARR reduction!
Henry Han (@HanCardiomd) profile pictureHenry Han
@HanCardiomdNov 7
#Hyperaldosteronism Remission after Extended #Aldosterone Synthase Inhibition 14-patient cohort: Improvements persisted up to 2 years after treatment cessation. BP ⬇️ by approximately 25 mm Hg, with 23% estimated clinical success. 📌 Aldosterone-to-renin ratio: 210.0 → 1.29 at 1–2 years (n=9)—a 99.2% reduction (95% CI, 98.2–99.6). nejm.org/doi/full/10.1056/NE… #ScientificSessions26 #AHA26 @AHAScience
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
3
13
877
Hemodynamic effects of #semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled RCT nature.com/articles/s41591-0… @NatureMedicine #GLP1RA @AHAScience #ScientificSessions26 #AHA26
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
1
8
31
1,421
Effects of #semaglutide on cardiac structure and function in #HFpEF and obesity: a pre-specified CMR substudy of the #CAMEO-SEMA trial @Nature @AHAScience @AHAMeetings #ScientificSessions26 nature.com/articles/s41591-0…

Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection...

Nature Medicine - As presented at the 2026 AHA Scientific Sessions, a cardiac magnetic resonance substudy of the CAMEO-SEMA trial showed that semaglutide significantly improved cardiac structure...

nature.com
4
16
884
#Dapagliflozin for Renal Protection in Heart Transplant Recipients: #DAPARHT Trial 📍 430 heart transplant recipients randomized to dapagliflozin 10 mg vs placebo; median 7 years post-transplant. 📍 Dapagliflozin improved 12-month #eGFR change: +2.0 vs +0.3 mL/min/1.73 m² . Between-group difference: +1.7 mL/min/1.73 m² (95% CI 0.1–3.3; P=0.03) 📍 No unexpected safety signals; adverse events, including infections, were similar between groups. ahajournals.org/doi/10.1161/… #ScientificSessions26 #AHA26 @AHAScience @AHAMeetings @CircAHA #DAPARHT #SGLT2i #HeartTransplant #CardioRenal
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
2
7
15
875
The DAPAgliflozin for Renal protection in Heart Transplant recipients #DAPARHT trial
Image from Henry Han (@HanCardiomd)
1
124
IV iron in #HFpEF : The #IRONMET-HFpEF Randomized Trial 📍 65 patients randomized to ferric derisomaltose 1000 mg IV vs placebo; 98.5% completed 12-week follow-up. 📍 Peak VO₂ improved significantly: +1.2 vs +0.1 mL/kg/min; LS mean difference +1.1 mL/kg/min (95% CI 0.2–1.9), P=0.02 📍 Functional gains: anaerobic-threshold VO₂, 6-minute walk distance, and NYHA class all improved vs placebo; KCCQ-OSS was not significantly different. 📌 Iron stores were effectively repleted with higher TSAT and ferritin, with no serious adverse events attributed to ferric derisomaltose ahajournals.org/doi/10.1161/… @AHAScience #ScientificSessions26 #AHA26 #HFpEF #HeartFailure #IronDeficiency @CircAHA
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
1
14
1
38
2,002
@CircAHA @AHAScience @AHAMeetings #ScientificSessions26
Image from Henry Han (@HanCardiomd)
1
2
5
241
Iron Repletion in #HFpEF: An Endpoint Is Not Yet an Indication ahajournals.org/doi/10.1161/… @CircAHA @AHAScience @AHAMeetings #ScientificSessions26
Image from Henry Han (@HanCardiomd)
1
3
4
431
Effects of #Sotatercept on Cardiac Structure and Function in Combined Post- and Precapillary Pulmonary Hypertension in #HFpEF : Analysis of the #CADENCE Study ahajournals.org/doi/10.1161/… #ScientificSessions26 @AHAScience @AHAMeetings @CircAHA
Image from Henry Han (@HanCardiomd)
1
7
15
904
Intensive BP Lowering in Patients with Type 2 DM : #OPTIMAL-DIABETES Trial 👥📍 9,476 patients | Mean age 64.7 years | 62% women 📍 Achieved SBP: 121.8 vs 135.4 mm Hg (intensive vs standard), Median follow-up: 4.0 years 📍 Primary outcome: 6.0% vs 6.7% — HR 0.90 (95% CI 0.77–1.06), P=0.20 → no significant benefit ⚠️📍 Serious AEs: 14.9% vs 14.6% — similar between groups nejm.org/doi/full/10.1056/NE… #ScientificSessions26 #AHA26 @AHAScience @NEJM
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
1
20
2
61
5,035
Digital Health Intervention to Optimize #HeartFailure Management After Hospital Discharge in Brazil (#OPT-HF Trial) In 154 hospitalized HF patients (EF <50%) with GDMT gaps: 📍 90-day GDMT score: 10.5 vs 7.5
Adj diff +3.01 (95% CI 2.30–3.73), P<0.001 📍 Hospitalization: 10.3% vs 22.4%
RR 0.46 (95% CI 0.21–0.99) 📍 Better self-care and No significant mortality difference @CircHF #ScientificSessions26 #AHA26 #HeartFailure #GDMT #DigitalHealth ahajournals.org/doi/10.1161/…
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
2
11
1
27
1,225
#REDUCE Trial : #Spironolactone after Stroke 📍 Open-label RCT of 160 stroke survivors—add-on spironolactone (n=85) vs usual care (n=75). 📍 Primary endpoint: 3-month mean home #SBP 125.6 vs 133.3 mm Hg; difference −7.7 mm Hg (P=0.0002). At 6 months: −6.9 mm Hg (P=0.0004). 📍 BP target <130/80 mm Hg at 3 months: 52% vs 30% (P=0.01). 📍 Caveats: More BP meds at 3 months (2.6 vs 2.1), ~15% missing BP data, early closure (160/200 planned). Stroke/MI prevention remains unproven. #AHA26 @AHAScience
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
9
27
1,077
Intensive BP Control in Patients with Previous Ischemic #Stroke ( OPTIMAL-STROKE Trial) Intensive BP lowering after ischemic stroke/TIA ; Open-label RCT across 30 sites in 🇧🇷 
👥 4,368 participants | Mean age 63.9 years | 47.9% women 
🎯 SBP targets: <120 vs <140 mm Hg 
📉 Achieved mean SBP: 122.0 vs 135.2 mm Hg, excluding the first 3 months 
⏱️ Median follow-up: 3.9 years 📍Primary CV composite: 10.9% vs 13.5%
HR 0.79 (95% CI 0.67–0.94); P=0.007 📍More renal composite events with intensive treatment; serious AEs similar. nejm.org/doi/full/10.1056/NE… #AHA26 @AHAScience @NEJM
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
Image from Henry Han (@HanCardiomd)
7
15
751
𝐉𝐮𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝! Original Article by S.E. Nissen et al.: Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a) eviden.cc/4eQEutM #ScientificSessions26 | @AHAScience
The image contains six graphs. Graph A: The cumulative incidence of four-component primary end point of major adverse cardiovascular events (MACE) on treatment. Graph B: The cumulative incidence of three-component MACE on treatment. Graph C: The cumulative incidence of three-component MACE on treatment for composite of nonfatal MI, urgent coronary revascularization, or coronary heart disease (CHD) death. Graph D: The first and total_MACE events. Graph E: The cumulative incidence of the four-component MACE primary end point in landmark analysis with stratification of the pelacarsen group by lipoprotein(a) reduction after 3 months of treatment greater than or equal to and less than the median (170 nmol/l). Graph F: The cumulative incidence of the four-component MACE primary end point in landmark analysis with stratification of the pelacarsen group by achieved lipoprotein(a) after 3 months of treatment less than or equal to and greater than the median (69.5 nmol/l).

ALT The image contains six graphs. Graph A: The cumulative incidence of four-component primary end point of major adverse cardiovascular events (MACE) on treatment. Graph B: The cumulative incidence of three-component MACE on treatment. Graph C: The cumulative incidence of three-component MACE on treatment for composite of nonfatal MI, urgent coronary revascularization, or coronary heart disease (CHD) death. Graph D: The first and total_MACE events. Graph E: The cumulative incidence of the four-component MACE primary end point in landmark analysis with stratification of the pelacarsen group by lipoprotein(a) reduction after 3 months of treatment greater than or equal to and less than the median (170 nmol/l). Graph F: The cumulative incidence of the four-component MACE primary end point in landmark analysis with stratification of the pelacarsen group by achieved lipoprotein(a) after 3 months of treatment less than or equal to and greater than the median (69.5 nmol/l).

17
5
33
11,350
Load more